二甲双胍对冠心病患者代谢综合征的影响  

Influence of Metformin on Metabolic Syndrome in Patients With Coronary Artery Disease

作　　者：陈华发[1] 谭健锹[1] 周荣辉[1] 朱可云[1] 陶卫国[1] 梁转合[1] 

机构地区：[1]江门市新会区人民医院心内科,广东省江门529100

出　　处：《中国基层医药》2010年第1期44-46,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨二甲双胍对冠心病患者代谢综合征的影响。方法52例冠心病合并代谢综合征（MS）患者随机分为对照组20例和观察组32冽，分别采用冠心病标准治疗以及在此基础上加用二甲双胍治疗，追踪时间为1年。对两组治疗前后的空腹血糖（FPG）、餐后2h血糖、空腹胰岛素（FINS）、甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白-胆固醇（HDL-C）、胰岛素抵抗指数（IRI）等指标进行比较，同时比较治疗后两组之间上述指标以及心血管事件发生率。结果与对照组比较，观察组患者治疗后FPG,餐后2h血糖、FINS、TG、IRI均明显下降（P〈0．05），其心血管事件发生率也明显低于对照组（P〈0．05）。结论二甲双胍能降低冠心病合并MS患者的血糖、TG、BMI和FINS，改善胰岛素敏感度，全面控制心血管危险因素，保护心血管免受损害，减少心血管事件的发生率，使患者多方获益。Objective To investigate the influence of metformin on metabolic syndrome in patients with coronary artery disease. Methods 52 patients with coronary artery disease and metabolic syndrome were randomly assigned into 2 groups, the control group with 20 cases and the study group with 32 cases. All the patients were treated with standard coronary artery disease therapy and meanwhile the study group was administered with metformin in addition to the basic therapy above. The follow-up time is one year. FPG,2h postprandial glucose,FINS,TG,TC,HDL-C, insulin resistance index and other standards were compared before and after the therapy, and between the 2 groups when the observation was finished. The rate of cardiovascular events was also compared between the 2 groups. Results Compared with the control group, the study group had lower levels of FPG, 2h postprandial glucose, FINS, TG and insulin resistance index when the therapy was completed （ P 〈 0.05 ）, and the rate of cardiovascular events was also lower （P 〈 0. 05）. Conclusion Mefformin could lower the levels of glucose, FINS, BMI, TG and insulin resistance index in patients with coronary artery disease and metabolic syndrome. Thus, it could reduce and undermine cardiovascular risk factors, protect the cardiovascular system, reduce the rate of cardiovascular events, which fully benefits the patients.

关 键 词：冠状动脉疾病 代谢综合征 二甲双胍 

分 类 号：R541[医药卫生—心血管疾病] R589[医药卫生—内科学]